4-(4-(4-Fluorophenyl)piperazin-1-yl)-6-methylpyrimidin-2-amine

Catalog No. :
ACHKTX565
CAS No. :
873839-03-3
Molecular Formula :
C15H18FN5
Molecular Weight :
287.34

IUPAC Name:4-(4-(4-fluorophenyl)piperazin-1-yl)-6-methylpyrimidin-2-amine

4-(4-(4-Fluorophenyl)piperazin-1-yl)-6-methylpyrimidin-2-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$240.00Login to see priceInquiryInquiry
5g95%$721.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4-(4-Fluorophenyl)piperazin-1-yl)-6-methylpyrimidin-2-amine
IUPAC Name4-(4-(4-fluorophenyl)piperazin-1-yl)-6-methylpyrimidin-2-amine
MDL No.MFCD00245876
Molecular FormulaC15H18FN5
Molecular Weight287.34
SMILESNC1=NC(N2CCN(C3=CC=C(F)C=C3)CC2)=CC(C)=N1
InChI KeyYRROOFFSKFANIU-UHFFFAOYSA-N
Synonym2-Amino-4-[4-(4-fluorophenyl)piperazin-1-yl]-6-methylpyrimidine;4-[4-(4-Fluorophenyl)piperazin-1-yl]-6-methylpyrimidin-2-amine;2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-piperazinyl]-6-methyl-
CAS No.873839-03-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACHKTX565 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQBMC283 route compound structure diagram
    ACQBMC2833977-29-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHKTX565 route product structure diagram
    ACHKTX565873839-03-3
Inquiry

2. ACHKTX565 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHKTX565 route product structure diagram
    ACHKTX565873839-03-3
Inquiry

Comments (0)